Since RAS-mutant cancer cells exhibit higher activity of both CK1α and the 20 S/26 S proteasome, we postulated that D4476 might potentiate the therapeutic efficacy of the clinically approved proteasome inhibitor Bortezomib. Here, CSNK1A1 is linked to cancer.